Drug Targeting Basic Defect Will Receive FDA Priority Review
A potential new CF therapy under FDA review, Kalydeco™, could be a major step forward in cystic fibrosis treatment.
Speaking Out to Make a Change
CF Foundation Advocates bring about big changes at the state level.
Going to College with CF
A college sophomore details the fun and challenges of college life while managing cystic fibrosis.
New Research Collaboration Takes Aim at Most Common CF Mutation
The Cystic Fibrosis Foundation teams up with one of the world’s largest pharmaceutical companies to find new therapies for people with the Delta F508 mutation.